BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

(2015) Filip Janku et al.   Oncotarget

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

(2013) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate

(2013) Bérengère Gobin et al.   CANCER LETTERS

Regulation of angiogenesis by PI3K signaling networks

(2013) Mariona Graupera et al.   EXPERIMENTAL CELL RESEARCH

MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma

(2013) Guangyi Zhao et al.   PLoS One

Current Therapeutic Strategies and Novel Approaches in Osteosarcoma

(2013) Kosei Ando et al.   Cancers

Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K–Akt signaling

(2012) Kelai Wang et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

(2012) Irene Brana et al.   BMC Medicine

The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies

(2012) Emmanouil Fokas et al.   CANCER AND METASTASIS REVIEWS

Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through protein kinase B-mediated vesicle transport

(2012) Masahiro Shinohara et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Alteration of Cellular Behavior and Response to PI3K Pathway Inhibition by Culture in 3D Collagen Gels

(2012) Brian Fallica et al.   PLoS One

Pericyte-Like Progenitors Show High Immaturity and Engraftment Potential as Compared with Mesenchymal Stem Cells

(2012) Amina Bouacida et al.   PLoS One

Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling

(2012) Pierre Guihard et al.   STEM CELLS

Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway

(2012) Masanobu Tsubaki et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolismin vivo

(2011) Greg C. Smith et al.   BIOCHEMICAL JOURNAL

High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes

(2011) Edwin Choy et al.   CANCER

Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases

(2011) Oscar Vadas et al.   Science Signaling

Updating progress in sarcoma therapy with mTOR inhibitors

(2010) J.- Y. Blay   ANNALS OF ONCOLOGY

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations

(2010) Shingo Dan et al.   CANCER RESEARCH

Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process

(2010) G. Moriceau et al.   CANCER RESEARCH

Specific Roles of the p110α Isoform of Phosphatidylinsositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation

(2010) Victoria Rotter Sopasakis et al.   Cell Metabolism

Therapeutic Approach of Primary Bone Tumours by Bisphosphonates

(2010) G. Moriceau et al.   CURRENT PHARMACEUTICAL DESIGN

Emerging drugs for high-grade osteosarcoma

(2010) Claudia Maria Hattinger et al.   EXPERT OPINION ON EMERGING DRUGS

Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis

(2010) Marc Baud'Huin et al.   JOURNAL OF PATHOLOGY

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Dysregulation of bone remodeling by imatinib mesylate

(2009) K. Vandyke et al.   BLOOD

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma

(2009) Ayesha Abdeen et al.   CANCER

Targeting Sarcomas: Novel Biological Agents and Future Perspectives

(2009) Devalingam Mahalingam et al.   CURRENT DRUG TARGETS